231 related articles for article (PubMed ID: 18718537)
21. Toxicity of MPTP on neurotransmission in three mouse models of Parkinson's disease.
Pain S; Gochard A; Bodard S; Gulhan Z; Prunier-Aesch C; Chalon S
Exp Toxicol Pathol; 2013 Jul; 65(5):689-94. PubMed ID: 23083629
[TBL] [Abstract][Full Text] [Related]
22. Dopaminergic lesioning impairs adult hippocampal neurogenesis by distinct modification of α-synuclein.
Schlachetzki JC; Grimm T; Schlachetzki Z; Ben Abdallah NM; Ettle B; Vöhringer P; Ferger B; Winner B; Nuber S; Winkler J
J Neurosci Res; 2016 Jan; 94(1):62-73. PubMed ID: 26451750
[TBL] [Abstract][Full Text] [Related]
23. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse.
German DC; Nelson EL; Liang CL; Speciale SG; Sinton CM; Sonsalla PK
Neurodegeneration; 1996 Dec; 5(4):299-312. PubMed ID: 9117541
[TBL] [Abstract][Full Text] [Related]
24. SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease.
Ago Y; Kawasaki T; Nashida T; Ota Y; Cong Y; Kitamoto M; Takahashi T; Takuma K; Matsuda T
Neuropharmacology; 2011 Dec; 61(8):1441-51. PubMed ID: 21903118
[TBL] [Abstract][Full Text] [Related]
25. Hippocampal damage and white matter lesions contribute to cognitive impairment in MPTP-lesioned mice with chronic cerebral hypoperfusion.
Gao Y; Tang H; Nie K; Zhu R; Gao L; Feng S; Wang L; Zhao J; Huang Z; Zhang Y; Wang L
Behav Brain Res; 2019 Aug; 368():111885. PubMed ID: 30959125
[TBL] [Abstract][Full Text] [Related]
26. Effects of chronic aspartame consumption on MPTP-induced Parkinsonism in male and female mice.
Amin SN; Hassan SS; Rashed LA
Arch Physiol Biochem; 2018 Oct; 124(4):292-299. PubMed ID: 29096532
[TBL] [Abstract][Full Text] [Related]
27. Quantitative analysis of dopaminergic loss in relation to functional territories in MPTP-treated monkeys.
Jan C; Pessiglione M; Tremblay L; Tandé D; Hirsch EC; François C
Eur J Neurosci; 2003 Oct; 18(7):2082-6. PubMed ID: 14622241
[TBL] [Abstract][Full Text] [Related]
28. Serotonin and dopamine depletion in distinct brain regions may cause anxiety in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice as a model of early Parkinson's disease.
Yang R; Ye S; Zhang S; Huang H; Zhang Y; Yang Y; Xie S; He L; Yang Y; Shi J
Neuroreport; 2023 Aug; 34(11):551-559. PubMed ID: 37384936
[TBL] [Abstract][Full Text] [Related]
29. Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis.
Date I; Felten DL; Felten SY
Brain Res; 1990 Jun; 519(1-2):266-76. PubMed ID: 1975765
[TBL] [Abstract][Full Text] [Related]
30. Alteration of the PAC1 Receptor Expression in the Basal Ganglia of MPTP-Induced Parkinsonian Macaque Monkeys.
Feher M; Gaszner B; Tamas A; Gil-Martinez AL; Fernandez-Villalba E; Herrero MT; Reglodi D
Neurotox Res; 2018 May; 33(4):702-715. PubMed ID: 29230633
[TBL] [Abstract][Full Text] [Related]
31. Selective loss of dopaminergic neurons in the substantia nigra pars compacta after systemic administration of MPTP facilitates extinction learning.
Kinoshita K; Tada Y; Muroi Y; Unno T; Ishii T
Life Sci; 2015 Sep; 137():28-36. PubMed ID: 26209139
[TBL] [Abstract][Full Text] [Related]
32. Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease.
Prediger RD; Aguiar AS; Rojas-Mayorquin AE; Figueiredo CP; Matheus FC; Ginestet L; Chevarin C; Bel ED; Mongeau R; Hamon M; Lanfumey L; Raisman-Vozari R
Neurotox Res; 2010 Feb; 17(2):114-29. PubMed ID: 19629612
[TBL] [Abstract][Full Text] [Related]
33. H MRS identifies lactate rise in the striatum of MPTP-treated C57BL/6 mice.
Koga K; Mori A; Ohashi S; Kurihara N; Kitagawa H; Ishikawa M; Mitsumoto Y; Nakai M
Eur J Neurosci; 2006 Feb; 23(4):1077-81. PubMed ID: 16519673
[TBL] [Abstract][Full Text] [Related]
34. 14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's disease.
Ding H; Underwood R; Lavalley N; Yacoubian TA
Neuroscience; 2015 Oct; 307():73-82. PubMed ID: 26314634
[TBL] [Abstract][Full Text] [Related]
35. Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse.
Araki T; Mikami T; Tanji H; Matsubara M; Imai Y; Mizugaki M; Itoyama Y
Eur J Pharm Sci; 2001 Jan; 12(3):231-8. PubMed ID: 11113642
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson's disease.
Pupyshev AB; Tikhonova MA; Akopyan AA; Tenditnik MV; Dubrovina NI; Korolenko TA
Pharmacol Biochem Behav; 2019 Feb; 177():1-11. PubMed ID: 30582934
[TBL] [Abstract][Full Text] [Related]
37. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice.
Mori A; Ohashi S; Nakai M; Moriizumi T; Mitsumoto Y
Neurosci Res; 2005 Mar; 51(3):265-74. PubMed ID: 15710490
[TBL] [Abstract][Full Text] [Related]
38. Tripchlorolide protects against MPTP-induced neurotoxicity in C57BL/6 mice.
Hong Z; Wang G; Gu J; Pan J; Bai L; Zhang S; Chen SD
Eur J Neurosci; 2007 Sep; 26(6):1500-8. PubMed ID: 17714494
[TBL] [Abstract][Full Text] [Related]
39. Executive function deficits and glutamatergic protein alterations in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Pflibsen L; Stang KA; Sconce MD; Wilson VB; Hood RL; Meshul CK; Mitchell SH
J Neurosci Res; 2015 Dec; 93(12):1849-64. PubMed ID: 26332770
[TBL] [Abstract][Full Text] [Related]
40. The effect of striatal pre-enkephalin overexpression in the basal ganglia of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Bissonnette S; Muratot S; Vernoux N; Bezeau F; Calon F; Hébert SS; Samadi P
Eur J Neurosci; 2014 Jul; 40(2):2406-16. PubMed ID: 24750443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
